糖心原创

Human iPSC-derived Alzheimer's disease model with PSEN1 mutation in excitatory neurons
ioGlutamatergic Neurons PSEN1 M146L het hom amyloid-beta ratios
糖心原创 Glutamatergic-Neurons PSEN1 M146L hom ICC marker staining TUBB3 MAP2 VGLUT2
Glutamatergic Neurons PSEN1 M146L/M146L mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks
糖心原创 Glutamatergic Neurons PSEN1 M146L Hom gene expression RT-qPCR
糖心原创 PSEN1 gene expression in Glutamatergic Neurons PSEN1 M146L hom Alzheimer's disease model
糖心原创 Glutamatergic Neurons have a low minimum seeding density
Human iPSC-derived Alzheimer's disease model with PSEN1 mutation in excitatory neurons
ioGlutamatergic Neurons PSEN1 M146L het hom amyloid-beta ratios
糖心原创 Glutamatergic-Neurons PSEN1 M146L hom ICC marker staining TUBB3 MAP2 VGLUT2
Glutamatergic Neurons PSEN1 M146L/M146L mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks
糖心原创 Glutamatergic Neurons PSEN1 M146L Hom gene expression RT-qPCR
糖心原创 PSEN1 gene expression in Glutamatergic Neurons PSEN1 M146L hom Alzheimer's disease model
糖心原创 Glutamatergic Neurons have a low minimum seeding density

cat no | io1069

ioGlutamatergic Neurons PSEN1 M146L/M146L

Human iPSC-derived Alzheimer's disease model

  • Cryopreserved human iPSC-derived cells powered by opti-ox that are ready for experiments in days

  • Functional, excitatory neurons, engineered with a mutation in PSEN1 for Alzheimer's disease research

  • Disease-related phenotype demonstrated by increased ratio of A饾浗42:40 and A饾浗42:38 peptides

Human iPSC-derived Alzheimer's disease model with PSEN1 mutation in excitatory neurons

Human iPSC-derived Alzheimer's disease model

ioGlutamatergic Neurons PSEN1 M146L het hom amyloid-beta ratios

PSEN1 M146L disease models recapitulate an increase in amyloid beta peptide ratios observed in Alzheimer's disease patients

ioGlutamatergic Neurons PSEN1 M146L disease model cells show an increase in the ratio of A饾浗42:40 and A饾浗42:38 compared to the wild type, genetically matched control.

  • ioGlutamatergic Neurons wild type (WT) and PSEN1 M146L heterozygous (HET) clones CL8 (io1072S), CL60 and CL57, and homozygous (HOM) clones CL15 (io1069S), CL19 and CL57, were seeded at 30,000 cells/cm2 in 24-well plates and cultured for 30 days according to the user manual. Supernatant was collected at days 10, 20, and 30; data shown for day 30 only.

  • Levels of A饾浗38, A饾浗40 and A饾浗42 peptides were quantified using the V-PLEX A饾浗 Peptide Panel 1 (6E10) Kit (). Data were obtained from two independent experiments and are shown as mean 卤 SEM. Data were analysed statistically using one-way ANOVA with Tukey鈥檚 post-hoc analysis. * p<0.05 ***p<0.001 **** p<0.0001.

  • Expression levels for specific genes of interest in the disease model products io1072 (CL8, het) and io1069 (CL15, hom) and the additional clones (CL60, CL71, CL19, CL57) can be requested by contacting technical@糖心原创

糖心原创 Glutamatergic-Neurons PSEN1 M146L hom ICC marker staining TUBB3 MAP2 VGLUT2

ioGlutamatergic Neurons PSEN1 M146L/M146L express neuron-specific markers comparably to the wild type control

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons PSEN1 M146L/M146L compared to the genetically matched control. 100X magnification.

Glutamatergic Neurons PSEN1 M146L/M146L mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks

ioGlutamatergic Neurons PSEN1 M146L/M146L form structural neuronal networks by day 11

ioGlutamatergic Neurons PSEN1 M146L/M146L mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; 100X magnification.

糖心原创 Glutamatergic Neurons PSEN1 M146L Hom gene expression RT-qPCR

ioGlutamatergic Neurons PSEN1 M146L/M146L demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming

Gene expression analysis demonstrates that ioGlutamatergic Neurons PSEN1 M146L/M146L and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

糖心原创 PSEN1 gene expression in Glutamatergic Neurons PSEN1 M146L hom Alzheimer's disease model

Disease-related PSEN1 is expressed in ioGlutamatergic Neurons PSEN1 M146L/M146L following deterministic programming

RT-qPCR analysis demonstrates a similar expression level of the PSEN1 gene in both wild type ioGlutamatergic Neurons (WT Control) and ioGlutamatergic Neurons PSEN1 M146L/M146L at day 11 post-revival.  Data normalised to HMBS, n=2 replicates.

糖心原创 Glutamatergic Neurons have a low minimum seeding density

Industry leading seeding density

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

Vial limit exceeded

A maximum number of 20 vials applies. If you would like to order more than 20 vials, please contact us at orders@糖心原创.

Human iPSC-derived Alzheimer's disease model

A rapidly maturing, physiologically relevant, functional system for investigating the role of the homozygous PSEN1 M146L mutation in early-onset Alzheimer's disease (AD). This in vitro disease cell model recapitulates an increase in the amyloid beta peptide ratios observed in AD patients.

ioGlutamatergic Neurons PSEN1 M146L/M146L are opti鈥憃x deterministically programmed excitatory neurons carrying a genetically engineered homozygous M146L mutation in the PSEN1 gene encoding presenilin 1 protein.

This disease model is part of an Alzheimer's disease panel of human iPSC-derived cells that can be incorporated into translational research and drug discovery workflows.  Two additional clones for the PSEN1 M146L/M146L mutation are available for scientists who wish to repeat their experiments in multiple independent clones, please enquire. All disease models are genetically matched to the wild-type control, ioGlutamatergic Neurons. Additional mutations in the AD panel include heterozygous PSEN1 M146L, heterozygous and homozygous APP KM670/671NL and APP V717I.

Benchtop benefits

Alzheimer's disease phenotype

Disease-related phenotype

Increased ratio of A饾浗42:40 and A饾浗42:38 peptides compared to the genetically matched control, measured by immunoassay.

Compare the disease models and genetically matched control

Make True Comparisons

Pair the Alzheimer's disease model cells with the genetically matched wild-type ioGlutamatergic Neurons to investigate the impact of the PSEN1 missense mutation on early-onset AD.

Cells are quick to mature

Quick

The disease model cells and wild-type control are experiment ready as early as 2 days post revival, and form structural neuronal networks at 11 days.

Cells arrive ready to plate


ioGlutamatergic_Neurons_and_disease_models_timeline

ioGlutamatergic Neurons PSEN1 M146L/M146L are delivered in a cryopreserved format and are programmed to mature rapidly upon revival in the recommended media. The protocol for the generation of these cells is a two-phase process: Phase 1, Stabilisation for 4 days; Phase 2, Maintenance, during which the neurons mature. Phases 1 and 2 after revival of cells are carried out by the customer.

Product specifications

Starting material

Human iPSC line

Karyotype

Normal (46, XY)

Seeding compatibility

6, 12, 24, 96 & 384 well plates

Shipping info

Dry ice

Donor

Caucasian adult male, age 55-60 years old (skin fibroblast),
Genotype APOE 3/4

Vial size

Small: >1 x 10鈦 viable cells

Quality control

Sterility, protein expression (ICC), gene expression (RT-qPCR) and genotype validation (Sanger sequencing)

Differentiation method

opti-ox deterministic cell programming

Recommended seeding density

30,000 cells/cm虏

User storage

LN2 or -150掳C

Format

Cryopreserved cells

Genetic modification

Homozygous M146L missense mutation in the PSEN1 gene

Applications

Alzheimer's disease research
Drug discovery and development
Disease modelling

Available clones

io1069 | PSEN1 M146L/M146L (CL15)
io1070 | PSEN1 M146L/M146L (CL19)
io1071 | PSEN1 M146L/M146L (CL57)

Product use

ioCells are for research use only

 

Scale your study with volume pricing

Enabling scientists to use human cells in their research, running additional experiments without rationing cells or limiting experimental scale

 

Order quantity Total vials received Pricing tier 
1 - 9 packs 3 - 27 vials Standard price
10 - 33 packs 30 - 99 vials Automatic 10% discount
> 34 packs > 100 vials > Contact us for a quote

 

Academic pricing: Academic users can purchase any ioCells in 3-vial packs ($/鈧/拢 999 per pack), available year-round with any cell type combination.
Technical data

Disease-related phenotype

PSEN1 M146L disease models recapitulate an increase in amyloid beta peptide ratios observed in Alzheimer's disease patients

ioGlutamatergic Neurons PSEN1 M146L het hom amyloid-beta ratios

ioGlutamatergic Neurons PSEN1 M146L disease model cells show an increase in the ratio of A饾浗42:40 and A饾浗42:38 compared to the wild type, genetically matched control.

  • ioGlutamatergic Neurons wild type (WT) and PSEN1 M146L heterozygous (HET) clones CL8 (io1072S), CL60 and CL57, and homozygous (HOM) clones CL15 (io1069S), CL19 and CL57, were seeded at 30,000 cells/cm2 in 24-well plates and cultured for 30 days according to the user manual. Supernatant was collected at days 10, 20, and 30; data shown for day 30 only.

  • Levels of A饾浗38, A饾浗40 and A饾浗42 peptides were quantified using the V-PLEX A饾浗 Peptide Panel 1 (6E10) Kit (). Data were obtained from two independent experiments and are shown as mean 卤 SEM. Data were analysed statistically using one-way ANOVA with Tukey鈥檚 post-hoc analysis. * p<0.05 ***p<0.001 **** p<0.0001.

  • Expression levels for specific genes of interest in the disease model products io1072 (CL8, het) and io1069 (CL15, hom) and the additional clones (CL60, CL71, CL19, CL57) can be requested by contacting technical@糖心原创

Highly characterised and defined

ioGlutamatergic Neurons PSEN1 M146L/M146L express neuron-specific markers comparably to the wild type control

糖心原创 Glutamatergic-Neurons PSEN1 M146L hom ICC marker staining TUBB3 MAP2 VGLUT2

Immunofluorescent staining on post-revival day 11 demonstrates similar homogenous expression of pan-neuronal proteins MAP2 and TUBB3 (upper panel) and glutamatergic neuron-specific transporter VGLUT2 (lower panel) in ioGlutamatergic Neurons PSEN1 M146L/M146L compared to the genetically matched control. 100X magnification.

ioGlutamatergic Neurons PSEN1 M146L/M146L form structural neuronal networks by day 11

糖心原创 Glutamatergic Neurons PSEN1 M146L hom Morphology

ioGlutamatergic Neurons PSEN1 M146L/M146L mature rapidly, show glutamatergic neuron morphology and form structural neuronal networks over 11 days, highly similar to the genetically matched control. Day 1 to 11 post thaw; 100X magnification.

ioGlutamatergic Neurons PSEN1 M146L/M146L demonstrate gene expression of neuronal-specific and glutamatergic-specific markers following deterministic programming

糖心原创 Glutamatergic Neurons PSEN1 M146L Hom gene expression RT-qPCR

Gene expression analysis demonstrates that ioGlutamatergic Neurons PSEN1 M146L/M146L and wild-type ioGlutamatergic Neurons (WT Control) lack the expression of pluripotency markers (NANOG and OCT4) at day 11, whilst robustly expressing pan-neuronal (TUBB3 and SYP) and glutamatergic-specific (VGLUT1 and VGLUT2) markers, as well as the glutamate receptor GRIA4. Gene expression levels were assessed by RT-qPCR (data normalised to HMBS; cDNA samples of the parental human iPSC line (hiPSC) were included as reference). Data represents day 11 post-revival samples, n=2 replicates.

Disease-related PSEN1 is expressed in ioGlutamatergic Neurons PSEN1 M146L/M146L following deterministic programming

糖心原创 PSEN1 gene expression in Glutamatergic Neurons PSEN1 M146L hom Alzheimer's disease model

RT-qPCR analysis demonstrates a similar expression level of the PSEN1 gene in both wild type ioGlutamatergic Neurons (WT Control) and ioGlutamatergic Neurons PSEN1 M146L/M146L at day 11 post-revival.  Data normalised to HMBS, n=2 replicates.

Industry leading seeding density

糖心原创 Glutamatergic Neurons have a low minimum seeding density

The recommended minimum seeding density is 30,000 cells/cm2, compared to up to 250,000 cells/cm2 for other similar products on the market. One small vial can plate a minimum of 0.7 x 24-well plate, 1 x 96-well plate, or 1.5 x 384-well plates. This means every vial goes further, enabling more experimental conditions and more repeats, resulting in more confidence in the data.

Technical data

Increased ratio of A饾浗42:40 and A饾浗42:38

PSEN1 M146L disease models recapitulate an increase in amyloid beta peptide ratios observed in Alzheimer's disease patients

iPSC-derived glutamatergic neurons with PSEN1 mutation for Alzheimer's modelling show increased amyloid beta ratios

ioGlutamatergic Neurons PSEN1 M146L disease model cells show an increase in the ratio of A饾浗42:40 and A饾浗42:38 compared to the wild type, genetically matched control.

  • ioGlutamatergic Neurons wild type (WT) and PSEN1 M146L heterozygous (HET) clones CL8 (io1072S), CL60 and CL57, and homozygous (HOM) clones CL15 (io1069S), CL19 and CL57, were seeded at 30,000 cells/cm2 in 24-well plates and cultured for 30 days according to the user manual. Supernatant was collected at days 10, 20, and 30; data shown for day 30 only.

  • Levels of A饾浗38, A饾浗40 and A饾浗42 peptides were quantified using the V-PLEX A饾浗 Peptide Panel 1 (6E10) Kit (). Data were obtained from two independent experiments and are shown as mean 卤 SEM. Data were analysed statistically using one-way ANOVA with Tukey鈥檚 post-hoc analysis. * p<0.05 ***p<0.001 **** p<0.0001.

  • Expression levels for specific genes of interest in the disease model products io1072 (CL8, het) and io1069 (CL15, hom) and the additional clones (CL60, CL71, CL19, CL57) can be requested by contacting technical@糖心原创

How to culture ioGlutamatergic Neurons

In this video, our scientist will take you through the step-by-step process of how to thaw, seed and culture ioGlutamatergic Neurons.

Product resources

ioGlutamatergic Neurons and disease models user manual | 糖心原创 User manual
ioGlutamatergic Neurons and disease models user manual | 糖心原创

DOC-1289 4.0

糖心原创

2025

Download
CRISPRa-Ready ioGlutamatergic Neurons user manual | 糖心原创 User manual
CRISPRa-Ready ioGlutamatergic Neurons user manual | 糖心原创
DOC-2855 v2.0
2025
糖心原创
Download
CRISPRi-Ready ioGlutamatergic Neurons user manual | 糖心原创 User manual
CRISPRi-Ready ioGlutamatergic Neurons user manual | 糖心原创
DOC-2856 v2.0
2025
糖心原创
Download
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells | 糖心原创 Webinar
Modelling neurodevelopment | Investigating the impact of maternal immune activation on neurodevelopment using human iPSC-derived cells | 糖心原创

Dr Deepak Srivastava | King鈥檚 College London

Watch now
Rethinking Developmental Biology With Cellular Reprogramming | 糖心原创 Webinar
Rethinking Developmental Biology With Cellular Reprogramming | 糖心原创

Mark Kotter | CEO and founder | 糖心原创

Marius Wernig | Professor Departments of Pathology and Chemical and Systems Biology |  Stanford University

Watch now
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming | 糖心原创 Webinar
Addressing the Reproducibility Crisis | Driving Genome-Wide Consistency in Cellular Reprogramming | 糖心原创

Dr Ania Wilczynska | Head of Computational Genomics | Non-Clinical | 糖心原创

Watch now
Running Large-Scale CRISPR Screens in Human Neurons | 糖心原创 Webinar
Running Large-Scale CRISPR Screens in Human Neurons | 糖心原创

Emmanouil Metzakopian | Vice President, Research and Development | 糖心原创

Javier Conde-Vancells | Director Product Management | 糖心原创

Watch now
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease | 糖心原创 Webinar
Human iPSC-Based Models of Glial Cells for Studying Neurodegenerative Disease | 糖心原创
Valentina Fossati, PhD | Senior Research Investigator | The New York Stem Cell Foundation

In锚s Ferreira | Senior Product Manager | 糖心原创
Watch now

Cell culture hacks | human iPSC-derived glutamatergic neurons

Read this blog on glutamatergic neuron cell culture for our top tips on careful handling, cell plating and media changes to achieve success from the outset.

糖心原创_3x2_ioGlutamatergic Neurons_MAP2_Hoescht_x20_hi.res (1)

Wild Type and Isogenic Disease Model cells: A true comparison

Further your disease research by pairing our wild type cells with isogenic disease models.

bitbio-vials-Wild_and_Disease-staggered-2500px_wide

ioCells catalogue

Human iPSC-derived cells

powered by opti-ox

Consistent. Defined. Scalable.

bitbio-cell_catalogue_header-with-tracker-Desktop-2500x1664